Participated · Equity · Feb 2026

Medikabazaar operates a technology-driven B2B e-commerce platform that streamlines procurement of medical equipment and consumables for healthcare providers. The company has recently completed an operational reset that emphasized supply–chain integration and customer experience, helping revenues surpass ₹2,000 crore while achieving operating breakeven and a profitable EBITDA. Its marketplace shows consistent double-digit year-on-year growth, supported by deeper supplier partnerships and improved platform capabilities. Management plans to channel new capital into accelerating digital innovation, reinforcing category leadership, upgrading technology infrastructure, and widening its pan-India footprint. Positioned within an Indian healthcare sector forecast to reach $320 billion by FY28, Medikabazaar benefits from rising hospital capacity and a broader shift toward digital procurement. With an eye on becoming an "ecosystem orchestrator" for healthcare supply chains, the firm aims to capture value from trends such as platform consolidation and actionable AI.

Participated · Series D · Sep 2024

Qure.ai is a global AI health innovator whose software analyses chest X-rays, CT scans, point-of-care ultrasounds, and other medical images to flag conditions such as tuberculosis, pneumonia, lung cancer, stroke, and other neuro-critical findings. The company’s platforms are deployed in more than 4,800 sites across 105+ countries, helping clinicians and health workers shorten TB diagnosis times from roughly two weeks to just one to two days, even in remote regions with limited clinical staff. Its technology is already used on Mount Everest, in sub-Saharan Africa, and rural Southeast Asia to bring diagnostics to hard-to-reach populations. Qure.ai’s product suite supports early disease detection, triage, and care-pathway management for both public-health programs and commercial healthcare providers. The firm also collaborates with pharmaceutical and medical-device companies to accelerate research and treatment developments. Looking ahead, Qure.ai plans to build an open-source, multi-modal database and new AI algorithms for point-of-care ultrasound, further expanding its lung-health capabilities. Although the article does not disclose current revenue figures, the multimillion-dollar Gates Foundation grant underscores external confidence in Qure.ai’s impact and future growth trajectory.

Participated · Series C · Sep 2024

Redcliffe Labs operates an omnichannel diagnostics platform offering lab testing, an extensive collection network and home‑collection services. The company serves over 7 million patients across more than 220 cities via 80 labs and 2,000+ collection centers. It plans to expand into Tier II and III Indian cities, open new labs, enhance its collection network and scale home‑collection offerings. Growth has been supported by strategic acquisitions in North‑Western India and partnerships with diagnostic chains. Leadership hires include Ankur Shah as an independent director and Alka Saxena as CFO, and the company highlights NABL accreditation and Six Sigma practices. Financially, operating revenue grew 2.6x to ₹347 crore in FY23 while losses widened fivefold to ₹345.6 crore, reflecting rapid expansion investments. Redcliffe Lifetech is a Noida, India–based diagnostics company that delivers pathology and specialised testing through an omni-channel infrastructure. Its network comprises 22 labs across 14 cities, several of which are NABL accredited, supported by a fleet of 400 phlebotomists operating in 100+ cities and an offline network of 500 collection centres. The company offers more than 3,500 different pathology and specialised tests, including genetics, at affordable prices. Redcliffe plans to expand its geographic reach across India with a focus on tier 2, 3 and 4 cities, scale its platform, and increase product offerings to radiology, disease data profiling and lifestyle management. Led by founder Dheeraj Jain, the business combines online channels, home sample collection, and an extensive offline footprint to reach consumers. The company will use the new funding to execute these expansion and product plans.

Participated · Series B · May 2024

Red.Health (formerly StanPlus) operates ambulance and emergency-response services across multiple verticals including RED Ambulances, RED Assist, RED Priority Clinics and RED Academy following a 2023 rebrand and pivot. The company offers plug-and-play medical response integrations for hospitals, health apps and wearables and says it partners with more than 500 hospitals and operates with over 100 hospitals in 20 cities. It has expanded offerings to include air ambulance services in more than 500 cities and aims to grow to 40–50 cities. Red.Health plans to use new funding to enhance its dispatch system and further develop its product. The company reported revenue of Rs 100 crore in FY24 and aims to double revenue in FY25; its Indian subsidiary’s revenue rose 45% to Rs 67 crore in FY23 from Rs 46.13 crore in FY22. Reports indicate the startup has faced growth challenges and has had difficulty paying employee salaries; losses rose to Rs 31.74 crore over the reported period. StanPlus operates a fleet of Red Ambulances that can be booked online or by phone and provides plug-and-play medical-response capabilities to large hospitals, health apps and wearable operators. The company aims to cut ambulance expected time of arrival from 15 minutes to 8 minutes under its “First Minute, Last Mile” approach. It plans to scale operations to 500 hospitals and expand its Red Ambulance brand from five cities to 15 cities. Last year the company announced a plan to add 3,000 advanced life support ambulances across 30 cities over three years with a cumulative investment of roughly Rs 900 crore. StanPlus is headquartered in Hyderabad and was founded in 2016. Financially, the company has raised multiple rounds including a $20 million Series A in the latest financing and prior seed and angel rounds totaling $2.6 million. StanPlus operates medical-transportation services with a fleet of over 300 ambulances and more than 60 ambulance operators, handling an average of 60+ calls a day and serving 15 hospitals with over 2,000 beds. The company offers ambulance and advanced-life-support transport and plans to broaden coverage across all medical-transportation categories. StanPlus intends to expand its advanced-life-support fleet and scale geographically. It also plans to invest in cutting-edge technologies to improve service delivery. The company recently completed seed fundraising to support these growth and product plans.

Led · Series B · Mar 2024

Founded in 2017, CureSkin combines computer vision and dermatological expertise to diagnose conditions such as acne, pigmentation, and hair loss from a smartphone photo. Its AI engine analyzes more than 10 million skin pixels across 2,000 facial attributes and references a database of 50 million images to tailor treatments for over 65,000 consumer profiles. The platform has served roughly 1.5 million customers, with strong penetration in India’s Tier-II and Tier-III cities. Users receive curated product kits and ongoing follow-ups from in-house dermatologists, creating a full-stack tele-dermatology experience. CureSkin generates revenue by selling these treatment kits and consultation services through its app. With the new capital, management plans to deepen AI capabilities, broaden product offerings, and scale operations. To date, the company has raised more than $26 million in venture funding.